Newsfeeds - Spark Newswire

2 minute read

Recession Investing: 5 High Yield Dividend Stocks For A Downturn

August 3, 2:23 PM

As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their stock.

ABBV

2 minute read

Earnings

Looking Into Viatris’s Return On Capital Employed

By Benzinga Insights

June 3, 11:42 AM

According to Benzinga Pro, during Q1, Viatris (NASDAQ:VTRS) earned $399.20 million, a 251.33% increase from the preceding quarter. Viatris's sales decreased to $4.19 billion, a 3.45% change since Q4.

VTRS

1 minute read

Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus

By Vandana Singh

May 9, 1:46 PM

Viatris Inc (NASDAQ:VTRS) reported Q1 FY22 sales of $4.18 billion, down 5% Y/Y (-1% on an operational basis), below the…

VTRS

2 minute read

27 Recession-Resistant Stocks To Look At Now

By AJ Fabino

May 9, 1:26 PM

When we enter a period of economic uncertainty, the phrase "recession-proof stocks" is tossed about, but really the only certainty is that recession-proof stocks do not exist. On the other hand, recession-resistant companies are what a savvy investor searches for during the absence of a bull market, as we are now.

ACI

1 minute read

Recap: Viatris Q1 Earnings

By Benzinga Insights

May 9, 7:10 AM

Viatris (NASDAQ:VTRS) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

VTRS

1 minute read

Viatris Q1 EPS $0.33 May Not Compare To $0.83 Estimate, Sales $4.19B Miss $4.23B Estimate

By Benzinga Newsdesk

May 9, 7:00 AM

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.33 per share which missed the analyst consensus estimate of $0.83 by 60.24 percent. This is a 64.13 percent decrease over earnings of $0.92 per share from the same

VTRS

16 minute read

Earnings Scheduled For May 9, 2022

By Benzinga Insights

May 9, 4:52 AM

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

ACM

1 minute read

News

Viatris Subsidiary Mylan Pharmaceuticals Conducting Voluntary Nationwide Recall Of One Batch Of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 Units/mL (U-100), Due To Potential For Missing Label In The Batch

By Benzinga Newsdesk

April 12, 4:17 PM

https://newsroom.viatris.com/2022-04-12-Mylan-Pharmaceuticals-Inc-,-a-Viatris-Company,-Conducting-Voluntary-Nationwide-Recall-of-One-Batch-of-Insulin-Glargine-Insulin-glargine-yfgn-Injection,-100-units-mL-U-100-,-Due-to-

VTRS

2 minute read

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight

By Shanthi Rexaline

April 3, 5:33 PM

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that moved stocks during the week.

ACAD

1 minute read

Viatris Says US Appeals Court Has Denied Biogen Request To Reconsider Its Prior Decision Affirming Invalidity Of Co.’s Tecfidera Patent

By Benzinga Newsdesk

March 17, 3:00 PM

-Reuters

BIIB